The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Darolutamide and time to pain progression by disease volume in ARASENS.
 
Matthew Raymond Smith
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Janssen Oncology; Lilly; Novartis; Pfizer
Research Funding - Bayer (Inst); ESSA (Inst); Janssen Oncology (Inst); Lilly (Inst); ORIC Pharmaceuticals (Inst)
 
Bertrand F. Tombal
Honoraria - AAA/Endocyte/Novartis; Amgen; Astellas Pharma; AstraZeneca; Bayer; Ferring; Janssen; MSD Oncology; Myovant Sciences; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen; Myovant Sciences; Pfizer/Astellas; Sanofi; Steba Biotech; Takeda
Speakers' Bureau - Amgen; Astellas Pharma; Astellas Pharma; Janssen
Research Funding - Ferring (Inst)
Expert Testimony - Steba Biotech
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Sanofi
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst)
Consulting or Advisory Role - Amgen (Inst); Arvinas; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); Macrogenics; MSD (Inst); Novartis (Inst); Orion; Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; MSD; Pfizer
 
Cora N. Sternberg
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Foundation Medicine; Genzyme; Gilead Sciences; Immunomedics; IMPAC Medical Systems; Incyte; Janssen Oncology; Janssen Oncology; Medscape; Merck; MSD; Pfizer; Roche; UroToday
 
E. David Crawford
Employment - Blue Earth Diagnostics (I)
Honoraria - Bayer
Consulting or Advisory Role - Bayer; Janssen Oncology; MDxHealth; Pfizer/Astellas; Tolmar
Speakers' Bureau - Bayer
 
Jeanny B. Aragon-Ching
Honoraria - Astellas Scientific and Medical Affairs Inc; Bristol-Myers Squibb; EMD Serono; Pfizer/EMD Serono
Consulting or Advisory Role - Algeta/Bayer; Amgen; AstraZeneca; AstraZeneca/MedImmune; AVEO; Bayer; Dendreon; EMD Serono; Exelixis; Immunomedics; Janssen Biotech; Merck; Pfizer; Pfizer/Myovant; Sanofi; Seagen
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Janssen-Ortho; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Algeta/Bayer; Astellas Pharma; Bristol Myers Squibb; Dendreon; EMD Serono
 
Martin Schostak
No Relationships to Disclose
 
Ronald Tutrone
No Relationships to Disclose
 
Ateesha F. Mohamed
Employment - Bayer HealthCare Pharmacuticals
 
Natasha Littleton
Employment - Bayer
 
Rui Li
Employment - Bayer
 
Shankar Srinivasan
Employment - Bayer
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; AstraZeneca; AstraZeneca; Clinical Care Options; Great Debates and Updates; Medscape; Merck; Precisca; Targeted Oncology; UroToday
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Convergent Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Janssen; Merck; Novartis; Pfizer; Tempus
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753